Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2025Frontiers in MedicineOpen Access

Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBo ChenYZYan ZhuYYYang Yang

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates treatment effects on kidney health in IgA nephropathy, suggesting optimized strategies.

Key Points

  • This study systematically investigates treatment efficacy variations in IgA nephropathy for improving kidney health and managing symptoms.
  • Conducted a systematic search in multiple databases up to February 20, 2025, analyzing 57 randomized controlled trials.
  • Employs pairwise and network meta-analyses for binary and continuous variables to assess treatment outcomes and ranks interventions.
  • Evaluates treatment effects on clinical remission, urinary protein excretion, kidney damage, and adverse events.
  • Tonsillectomy with steroids (RR = 8.23) and anti-APRIL monoclonal antibody (RR = 10.00) significantly improved clinical remission compared to placebo.
  • Telitacicept (SMD = -5.21) and steroids with RASI (SMD = -1.98) significantly reduced 24-h urinary protein excretion, outperforming alternative regimens.
  • Steroids combined with RASI reduced the risk of end-stage kidney disease or kidney damage by 98.1%, highlighting its efficacy.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/6a2b104f20f9105724102f34https://doi.org/10.3389/fmed.2025.1515723
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment of IgA Nephropathy with ACE Inhibitors2003 · 347 citations
  2. 2Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy2017 · 108 citations
  3. 3Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial2023 · 301 citations
  4. 4Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy2017 · 544 citations
  5. 5Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy2023 · 115 citations